TEM

Tempus AI, Inc.

15 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change

20%

bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action

40%

bullishMay 13

Replaced high-interest secured debt with 0% convertible notes to improve cash flow.

debt restructure

70%

bearishMay 13

Potential issuance of up to 9.3 million shares upon conversion of notes.

dilution risk

50%

neutralMay 13

Raised $460 million in aggregate principal amount via private offering.

capital raise

60%

bullishMay 13

Replaced high-interest secured debt with 0% convertible notes to improve cash flow.

debt restructure

70%

bearishMay 13

Potential issuance of up to 9.3 million shares upon conversion of notes.

dilution risk

50%

neutralMay 13

Raised $460 million in aggregate principal amount via private offering.

capital raise

60%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

bullishMay 5

Revenue grew 36% YoY to $348.1 million.

earnings beat

70%

bullishMay 5

Adjusted EBITDA improved from ($16.2M) to ($2.8M).

margin expansion

40%

bearishMay 5

Strict $1.1B revenue covenant creates significant default risk.

debt restructure

60%

bearishMay 5

Stock-based compensation expenses more than doubled to $52.7 million.

dilution risk

80%

Filing History

8-KMay 22, 2026

The 8-K filing confirms that Tempus AI has successfully navigated its 2026 annual meeting, securing the election of its board and the approval of its auditors. While the raw numbers suggest a unified front, the underlying tension between the concentrated voting power of Class B shares and the significant volume of abstentions highlights a divide in investor sentiment. The transition to a three-year executive pay review is the most material outcome, as it shifts the governance lens from immediate accountability to long-term strategic execution.

8-KMay 13, 2026

The 8-K filing reveals a decisive shift in Tempus AI's financing strategy, moving from traditional secured bank debt to the convertible bond market. While the immediate effect is a reduction in interest expense and the removal of secured liens, the long-term impact depends on the company's ability to scale its AI-driven healthcare analytics to support a $460 million liability. The successful upsizing of the offering suggests strong market demand, but the trade-off is a transition from cash-interest risk to equity-dilution risk. Investors must now weigh the benefit of an optimized balance sheet against the potential for a significant dilution event as the stock approaches the conversion price.

10-QMay 5, 2026

The Q1 2026 filing presents a classic high-growth, high-risk profile. Tempus AI has successfully proven that there is an aggressive appetite for its 'Intelligent Diagnostics' and data licensing products, as evidenced by the rapid top-line expansion and the securing of massive multi-year contracts. The shift toward a more positive Adjusted EBITDA suggests that the company is moving toward a sustainable scale, provided it can manage its overhead. However, the tension between rapid growth and financial stability is evident. The company is effectively racing against its own debt covenants and cash burn. The investment thesis now hinges on whether the revenue acceleration from the Ambry acquisition and the Pathos partnership can outpace the rising costs of SG&A and the looming pressure of its $1.1 billion revenue requirement. Investors are essentially betting on the company's ability to convert its data moat into a cash-flow engine before its liquidity runway or debt terms expire.